May 26 (Reuters) – Cardiovascular drug developer Kardigan on Tuesday filed for an initial public offering in the United States.
A rebound in biotech IPO issuance signals improving risk appetite in equity markets, as investors return to healthcare companies with advanced-stage drug pipelines and clearer paths toward commercialization.
Kardigan is a U.S.-based clinical-stage biotechnology company developing precision medicines for cardiovascular diseases. The company is advancing three late-stage experimental therapies.
Kardigan will list on the Nasdaq Global Market under the ticker symbol “KARD”.
J.P. Morgan, Jefferies, Leerink Partners and TD Cowen are the underwriters for the offering.
(Reporting by Prakhar Srivastava in Bengaluru; editing by Alan Barona)
Comments